Nivells de radó en exterior i recintes tancats a la marjal càrstica de Peníscola

S’ha portat a terme un mostreig de diferents punts de la Marjal de Peníscola i 7 instal·lacions properes amb la finalitat de determinar les concentracions de 222Rn en aire exterior i interior. Les anàlisis en els punts exteriors obtenen unes concentracions de 222Rn elevades, superiors a 50 Bq·m-3 en alguns punts. El fet que el sòl de la marjal tingui altes concentracions de 226Ra i elevades concentracions de 226Ra i 222Rn en l’aigua salobre poden justificar aquests valors. L’alta activitat de l’aigua, les característiques de l’edifici i mala gestió del sistema de clavegueram de Peníscola són els responsables de les elevades concentracions de 222Rn en l’aire interior de la depuradora, amb concentracions màximes de més de 70000 Bq·m-3. Un sistema de ventilació adequat com un extractor de PVC evitaria l’acumulació del 222Rn a l’interior de la instal·lació.

Why do convertible issuers simultaneously repurchase stock? An arbitrage-based explanation

We examine why firms combine convertible debt offerings with stock repurchases. In 2006, 33% of the convertible issuers in the US simultaneously repurchased stock. These combined transactions are inconsistent with traditional motivations for convertible issuance. We document that convertible arbitrage drives these stock repurchases. Convertible debt arbitrageurs simultaneously buy convertibles and short sell the issuer’s common stock, resulting in downward pressure on the stock price. To prevent such short-selling activity, firms repurchase their stock directly from arbitrageurs. We show that combined transactions exhibit lower short-selling activity and that convertible arbitrage explains both the size and speed of the stock repurchases.

Relationships between imatinib plasma levels and efficacy

Purpose: While imatinib has revolutionized the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal tumors (GIST), its pharmacokinetic-pharmacodynamic relationships have been poorly studied. This study aimed to explore the issue in oncologic patients, and to evaluate the specific influence of the target genotype in a GIST subpopulation. Patients and methods: Data from 59 patients (321 plasma samples) were collected during a previous pharmacokinetic study. Based on a population model purposely developed, individual post-hoc Bayesian estimates of pharmacokinetic parameters were derived, and used to estimate drug exposure (AUC; area under curve). Free fraction parameters were deduced from a model incorporating plasma alpha1-acid glycoprotein levels. Associations between AUC (or clearance) and therapeutic response (coded on a 3-point scale), or tolerability (4-point scale), were explored by ordered logistic regression. Influence of KIT genotype on response was also assessed in GIST patients. Results: Total and free drug exposure correlated with the number of side effects (p < 0.005). A relationship with response was not evident in the whole patient set (with good-responders tending to receive lower doses and bad-responders higher doses). In GIST patients however, higher free drug exposure predicted better responses. A strong association was notably observed in patients harboring an exon 9 mutation or a wild type KIT, known to decrease tumor sensitivity towards imatinib (p < 0.005). Conclusions: Our results are arguments to further evaluate the potential benefit of a therapeutic monitoring program for imatinib. Our data also suggest that stratification by genotype will be important in future trials.